查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018057

直接作用抗病毒藥物市場：依產品類型、治療領域、通路和最終用戶分類－2026-2032年全球市場預測

Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，直接作用抗病毒藥物市場價值將達到 138.7 億美元，到 2026 年將成長至 157.9 億美元，到 2032 年將達到 349.2 億美元，複合年成長率為 14.10%。

主要市場統計數據
基準年 2025 138.7億美元
預計年份：2026年 157.9億美元
預測年份 2032 349.2億美元
複合年成長率 (%) 14.10%

為了支持醫療保健相關人員的策略決策，我們將整理直接作用抗病毒療法的臨床、營運和商業性基礎。

直接抗病毒療法的出現徹底改變了病毒性肝病和感染疾病的治療方式，顯著改善了患者的預後，並重新定義了根治性治療路徑的預期。本文闡述了這些療法的臨床和商業性背景，重點關注作用機制的創新、治療藥物分類的演變及其對整個醫療保健系統的廣泛影響。此外，本文還總結了臨床開發的最新趨勢，例如療程縮短、耐受性提高以及對所有基因型均有效，說明了這些趨勢如何轉變治療模式，加速專家對這些療法的接受度。

臨床突破、分銷創新和監管調整如何匯聚，重新定義抗病毒療法的治療途徑和商業策略。

臨床進展，以及醫療服務體系和商業策略的轉變，正在加速直接抗病毒療法領域的變革。圍繞治療的討論正從漸進式改進轉向對治癒率和治療便利性的根本性期望，促使相關人員重新評估標準治療路徑和人群層面的根除策略。同時，藥理學的進步，特別是聯合治療在提高療效並最大限度降低抗藥性風險方面的進展，正在改變臨床試驗的設計和終點選擇，從而建立更高效的監管核准流程並擴大適應症範圍。

本研究評估了近期貿易政策和關稅趨勢如何重塑抗病毒療法的供應鏈韌性、籌資策略和採購慣例。

關稅的引入和貿易政策的調整會對藥品供應鏈、籌資策略和貿易經濟產生連鎖反應，進而影響臨床試驗的進行和生產計畫。關稅相關的成本會影響活性成分和輔料的選擇，促使製造商實現供應商多元化、重新評估區域生產基地並調整庫存緩衝。這些營運應對措施並非僅僅是戰術性的；它們會改變產品上市的前置作業時間，限制應對力，並增加與大規模機構投資者和政府採購負責人進行合約談判的複雜性。

多維細分洞察揭示了產品類型、治療領域、分銷管道和最終用戶趨勢如何獨特地影響策略和部署。

細分市場分析揭示了直接抗病毒藥物領域各個關鍵面向的需求促進因素、臨床特徵和分銷趨勢的差異。根據產品類型，市場可分為品牌學名藥，這種區分會影響定價趨勢、銷售管道支援以及確保產品滲透率和用藥依從性所需的商業性夥伴關係。品牌藥通常需要更多投資於教育、真實世界數據 (REW) 收集和專業分銷網路，而學名藥則更注重成本競爭力、大規模生產以及滲透到高效的分銷網路中。

美洲、歐洲、中東和非洲以及亞太地區的相對區域趨勢和戰略意義正在推動准入和部署方法的差異化。

區域趨勢是直接抗病毒藥物研發重點、監管參與策略和商業化計畫的關鍵因素。在美洲，支付方主導的合約、基於療效的協議以及強大的專業醫療網路影響著製造商如何參與處方藥清單和患者支持項目。監管機構和公共衛生舉措通常將根除感染疾病作為首要目標，這為製造商和公共部門採購方之間的合作創造了機會，從而協調高影響力干預措施的供需。

企業定位和競爭動態由創新領導力、生產規模和策略夥伴關係關係驅動，這些因素決定了企業在抗病毒治療領域的持續主導地位。

企業層面的發展趨勢反映了創新領導力、生產規模和策略聯盟的綜合作用，這些因素共同決定了企業在直接抗病毒藥物領域的競爭地位。創新製藥和生技公司致力於建構可靠的安全性和真實世界療效證據，以推動作用機制的差異化，拓展泛基因型適應症，並維持臨床偏好。這些企業通常會投資於整合臨床營運、藥物安全監測和數位化用藥依從性支援工具的生態系統能力，以支援永續的市場進入和醫生的信任。

產業領導者正在協調臨床證據、供應鏈韌性和管道特定的商業化，透過可操作的策略行動來加速產品普及並維持價值。

旨在掌握直接抗病毒藥物市場發展機會的領導者應採取一系列切實有效的措施，兼顧臨床可信度和營運韌性。首先，應儘早整合臨床開發和商業化計劃，確保試驗設計能夠產生與支付方、指南委員會和真實臨床實踐相關的證據。從一開始就協調終點指標、病患族群和健康經濟學證據需求，有助於企業縮短從核准到有效推廣的流程。

採用可重複的混合方法研究設計，結合專家的初步訪談、文獻整合、供應鏈映射和情境壓力測試，以確保獲得可靠的見解。

本研究採用混合方法，整合了定性訪談、文獻分析以及供應鏈和監管分析，以全面了解直接抗病毒藥物的市場環境。透過對經驗豐富的臨床醫生、藥物採納決策者、採購專家和行業高管進行結構化訪談，獲得了關鍵見解，從而能夠對臨床實踐模式、合約動態和營運挑戰進行三角驗證。文獻檢驗整合了同儕審查文獻、監管指導文件和公開的臨床試驗結果，以闡明治療效果、安全性以及監管趨勢的背景。

透過整合策略挑戰，確保永續的治療效果，強調臨床創新、營運韌性和協作准入模式的協調一致。

這份最終的綜合分析重申了直接抗病毒藥物領域經營團隊決策的核心主題：治療創新必須輔以切實可行的藥物取得、輸送和供應策略。臨床進展為重新思考治療途徑和公共衛生策略提供了契機，但研發、生產和市場進入部門之間的密切協調對於確保充分發揮其效益至關重要。業務永續營運，尤其是在供應商多元化和生產柔軟性方面，對於確保產品供應和履行公共衛生責任仍然至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 直接作用抗病毒藥物市場：依產品類型分類

  • 品牌藥品
  • 學名藥

第9章：依治療分類的直接抗病毒藥物市場

  • 聯合治療
  • Ns5A抑制劑
  • Ns5B抑制劑
  • 蛋白酶抑制劑

第10章：直接作用抗病毒藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 直接作用抗病毒藥物市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章 直接作用抗病毒藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 直接作用抗病毒藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 直接作用抗病毒藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國直接作用抗病毒藥物市場

第16章：中國直接抗病毒藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-032A67D91452

The Direct-acting Antiviral Drug Market was valued at USD 13.87 billion in 2025 and is projected to grow to USD 15.79 billion in 2026, with a CAGR of 14.10%, reaching USD 34.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.87 billion
Estimated Year [2026] USD 15.79 billion
Forecast Year [2032] USD 34.92 billion
CAGR (%) 14.10%

Contextualizing the clinical, operational, and commercial foundations of direct-acting antiviral therapies to frame strategic decision-making across healthcare stakeholders

The emergence of direct-acting antiviral therapies has permanently reshaped approaches to viral hepatology and infectious disease management, driving meaningful improvements in patient outcomes and redefining the expectations of curative treatment pathways. This introduction establishes the clinical and commercial context for these therapies, focusing on mechanism-of-action innovations, evolving therapeutic classes, and the broader implications for healthcare systems. It also synthesizes recent trends in clinical development where shorter regimens, improved tolerability, and pan-genotypic activity have shifted treatment paradigms and accelerated adoption among specialist clinicians.

From a supply-chain perspective, manufacturing complexity and active pharmaceutical ingredient sourcing have become central considerations for developers and purchasers alike. As a result, quality-by-design manufacturing, biologics-inspired process controls, and strategic supplier relationships are increasingly important for ensuring predictable product availability. Simultaneously, payer perspectives have evolved to emphasize long-term outcomes and cost-of-care reductions, which in turn influence formulary decisions and contracting strategies.

Looking ahead, integration of diagnostics, linkage-to-care programs, and decentralized treatment models will continue to shape the clinical deployment of direct-acting antivirals. Therefore, this introduction frames subsequent sections by outlining the intersections between clinical efficacy, operational deployment, regulatory oversight, and commercial execution that leaders must reconcile when advancing programs from development into routine clinical practice.

How clinical breakthroughs, distribution innovations, and regulatory adaptation are converging to redefine treatment pathways and commercial strategies for antiviral therapies

Transformative shifts are accelerating across the direct-acting antiviral landscape as clinical advances converge with changes in care delivery and commercial strategy. The therapeutic narrative has transitioned from incremental improvements to fundamentally different expectations around cure rates and treatment simplicity, prompting stakeholders to reevaluate standard-of-care pathways and population-level eradication strategies. Concurrently, advances in pharmacology-particularly combination regimens that enhance potency while minimizing resistance risk-have altered clinical trial designs and endpoint selection, leading to more efficient pathways for regulatory acceptance and label expansion.

In parallel, the distribution environment is undergoing a structural evolution. Digital health platforms and telemedicine have reduced barriers to diagnosis and treatment initiation, enabling earlier intervention and expanding the pool of patients who can be treated outside tertiary centers. These shifts have fostered closer collaboration between diagnostic developers, specialty clinics, and community providers, and they have required manufacturers to adopt more flexible commercialization models that support education, adherence, and monitoring within diverse care settings.

Regulatory frameworks have also adapted, with a stronger emphasis on real-world evidence and post-marketing surveillance to monitor long-term outcomes and safety in broader populations. As these transformative forces continue to interact, they create both opportunities and complexities for manufacturers, payers, and providers; stakeholders that proactively align clinical development with scalable delivery models will be best positioned to capture the full value inherent in the next generation of direct-acting antiviral therapies.

Assessing how recent trade policy and tariff developments have reshaped supply chain resilience, sourcing strategy, and procurement practices across antiviral therapeutics

The introduction of tariffs and trade policy adjustments has a cascading effect on pharmaceutical supply chains, procurement strategies, and transactional economics that extend into clinical access and manufacturing planning. Tariff-related costs influence sourcing choices for active pharmaceutical ingredients and excipients, prompting manufacturers to reassess supplier diversification, regional production footprints, and inventory buffers. These operational responses are not merely tactical; they alter lead times for product launch, constrain responsiveness to demand surges, and increase the complexity of contract negotiations with large institutional purchasers and government buyers.

Moreover, tariffs interact with regulatory and quality requirements in ways that complicate sourcing decisions. When suppliers in tariff-impacted jurisdictions also possess regulatory approvals or specialized manufacturing capabilities, firms face trade-offs between cost, compliance, and speed to market. In response, companies increasingly explore regional manufacturing partnerships, tolling arrangements, and vertical integration to mitigate exposure. At the same time, procurement organizations and payers are re-evaluating contracting structures to protect against price volatility and supply disruptions, favoring multi-year agreements or increased inventory commitments when necessary.

Importantly, tariffs also reshape strategic investment decisions. Firms planning capacity expansions, new product rollouts, or geographic entry must incorporate the altered cost dynamics into scenario planning and capital allocation. Through careful supply-chain redesign, proactive regulatory engagement, and contractual innovation, stakeholders can reduce exposure and preserve patient access, although these adjustments require deliberate cross-functional alignment to implement effectively and sustainably.

Multidimensional segmentation insights that illuminate how product type, therapeutic class, channels, and end-user dynamics uniquely influence strategy and deployment

Segmentation insight reveals how demand drivers, clinical profiles, and distribution dynamics differ across key dimensions of the direct-acting antiviral space. Based on Product Type, market is studied across Branded Drugs and Generic Drugs, and this distinction influences pricing dynamics, channel support, and the nature of commercial partnerships required to ensure uptake and adherence. Branded products often require heavier investments in education, real-world evidence generation, and specialty distribution, while Generic Drugs emphasize cost competitiveness, scale manufacturing, and efficient channel penetration.

Based on Therapeutic Class, market is studied across Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor, and Protease Inhibitor, and each class carries unique clinical positioning, resistance considerations, and regimen complexity that shape prescribing patterns. Combination Therapy often addresses multi-genotype coverage and resistance suppression, whereas class-specific agents may be prioritized where monotherapy still offers clinical advantage or where tolerability is paramount. This therapeutic segmentation has direct consequences for clinical trial design, labeling strategies, and post-approval lifecycle management.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which affects how products are accessed, how adherence is monitored, and how patient support programs are deployed. Hospital Pharmacy channels typically handle more complex cases and institutional contracting, while Online Pharmacy platforms enable broader patient reach and convenience. Based on End User, market is studied across Home Healthcare, Hospitals, and Specialty Clinics, and the end-user mix shapes training requirements, monitoring protocols, and the design of ancillary services required to ensure optimal outcomes. Taken together, these segmentation lenses provide a multidimensional view that informs product positioning, commercialization tactics, and partnership priorities.

Comparative regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that drive differentiated access and deployment approaches

Regional dynamics have become a decisive factor in shaping development priorities, regulatory engagement strategies, and commercialization planning for direct-acting antivirals. In the Americas, payer-driven contracting, outcomes-based agreements, and robust specialty care networks influence how manufacturers approach formulary access and patient support programs. Regulatory agencies and public health initiatives often prioritize elimination goals, which creates collaborative opportunities between manufacturers and public-sector purchasers to align supply and demand for high-impact interventions.

In Europe, Middle East & Africa, healthcare systems exhibit a breadth of procurement models and budgetary constraints that require nuanced market access strategies. Countries with centralized healthcare procurement may favor negotiated pricing and volume guarantees, whereas regions with heterogeneous payers necessitate adaptable contracting and evidence generation to meet divergent reimbursement thresholds. Meanwhile, supply-chain complexity and capacity variability across parts of Europe, the Middle East, and Africa underscore the need for regional manufacturing partnerships and tailored distribution solutions.

In Asia-Pacific, rapid scale-up of diagnostic and treatment programs, coupled with strong manufacturing capabilities in several countries, creates both competitive and collaborative opportunities. Diverse regulatory pathways and varying degrees of local production capacity make it critical to align product registrations, technology transfers, and commercial launches with country-specific requirements. Across all regions, successful strategies will integrate local clinical engagement, regionally appropriate pricing models, and resilient distribution networks to ensure broad and equitable access to antiviral therapies.

Corporate positioning and competitive dynamics driven by innovation leadership, manufacturing scale, and strategic partnerships that determine sustainable advantage in antiviral therapeutics

Company-level dynamics reflect a mix of innovation leadership, manufacturing scale, and strategic collaborations that collectively determine competitive positioning within the direct-acting antiviral space. Innovative pharmaceutical and biotech companies focus on advancing mechanism-of-action differentiation, expanding pan-genotypic indications, and generating robust safety and real-world effectiveness evidence to sustain clinical preference. These organizations typically invest in integrated ecosystem capabilities-combining clinical affairs, pharmacovigilance, and digital adherence tools-to support durable market access and physician confidence.

Meanwhile, manufacturers with strong generic capabilities emphasize operational excellence, cost optimization, and rapid scale-up to meet demand in price-sensitive markets. Contract manufacturing organizations and tolling partners play a pivotal role in enabling agility, allowing brand and generic players to adjust output in response to procurement cycles and supply shocks. Partnership strategies, including licensing agreements, co-promotion deals, and public-private collaborations, continue to shape the competitive landscape and accelerate treatment uptake in public health initiatives.

Across the corporate landscape, mid-size specialty companies and larger pharma firms differentiate through strategic investments in diagnostics integration, patient support programs, and targeted distribution partnerships. Leadership teams that align clinical differentiation with pragmatic commercialization models and resilient manufacturing networks will be better equipped to navigate regulatory complexity and sustain long-term value creation in this therapeutic area.

Practical strategic actions for industry leaders to align clinical evidence, supply-chain resilience, and channel-specific commercialization to accelerate access and sustain value

Leaders seeking to capitalize on the evolving direct-acting antiviral landscape should adopt a set of pragmatic, high-impact actions that balance clinical credibility with operational resilience. First, integrate clinical development and commercialization planning early so that trial designs generate evidence relevant to payers, guideline committees, and real-world practice. By aligning endpoints, patient populations, and health-economic evidence needs from the outset, organizations can shorten the pathway from approval to meaningful uptake.

Second, strengthen supply-chain resilience through supplier diversification, selective regional manufacturing partnerships, and flexible contract manufacturing arrangements. Scenario planning that incorporates potential trade-policy shifts, raw-material constraints, and demand volatility will enable more adaptive sourcing decisions. Third, tailor distribution and patient-support models to channel realities: design differentiated approaches for Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy that reflect variations in access, adherence, and monitoring requirements. Complement these channel strategies with robust diagnostic linkages and provider education initiatives to ensure appropriate patient selection and follow-through.

Finally, pursue collaborative pricing and contracting approaches with payers, including outcomes-based agreements where appropriate, and invest in data infrastructure to demonstrate value in routine practice. By combining these actions-evidence-aligned development, supply-chain robustness, channel-specific commercialization, and payer collaboration-industry leaders can enhance access, reduce variability in outcomes, and create defensible commercial positions.

A reproducible mixed-methods research design combining primary expert interviews, literature synthesis, supply-chain mapping, and scenario stress testing to ensure robust insights

This research employed a mixed-methods approach that integrates primary qualitative interviews, secondary literature synthesis, and supply-chain and regulatory analysis to produce a comprehensive view of the direct-acting antiviral environment. Primary insights were derived from structured interviews with experienced clinicians, formulary decision-makers, procurement specialists, and industry executives, enabling triangulation of clinical practice patterns, contracting dynamics, and operational challenges. Secondary analysis synthesized peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial outcomes to contextualize therapeutic efficacy, safety profiles, and regulatory trends.

In addition, supply-chain mapping and policy analysis were used to assess sourcing risks, manufacturing dependencies, and the implications of trade-policy shifts. Scenario-based stress testing helped illuminate how different tariff and procurement outcomes could affect operational decisions and stakeholder incentives. Evidence quality checks and cross-validation between internal sources and external subject-matter experts were implemented to ensure the robustness of conclusions.

Transparency in methodology supports reproducibility and allows stakeholders to appraise the fit of insights to their specific contexts. Where appropriate, the research highlights data limitations and recommends areas for targeted follow-up research or bespoke analysis to address organization-specific questions related to access, pricing strategies, and manufacturing expansion planning.

Synthesis of strategic imperatives emphasizing alignment between clinical innovation, operational resilience, and collaborative access models to secure sustainable therapeutic impact

This final synthesis reiterates the central themes that should guide executive decision-making in the direct-acting antiviral domain: therapeutic innovation must be matched with pragmatic strategies for access, delivery, and supply assurance. Clinical advances have created opportunities to rethink treatment pathways and public-health approaches, but capturing the benefits requires careful coordination across development, manufacturing, and market-access functions. Operational resilience-particularly around supplier diversification and manufacturing flexibility-remains essential to protecting product availability and upholding public-health commitments.

Moreover, segmentation and regional nuance matter. Decisions about product type, therapeutic class, distribution channel, and end-user settings will determine the traction a therapy achieves in different healthcare systems and will inform the investments needed across evidence generation, education, and logistics. Finally, collaborative arrangements-whether with payers, public-health agencies, or manufacturing partners-can accelerate access while sharing risk and aligning incentives around long-term outcomes. As organizations translate these conclusions into operational plans, they should prioritize alignment between clinical objectives and commercial realities, ensuring that strategy execution remains patient-centered and resilience-focused.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Direct-acting Antiviral Drug Market, by Product Type

  • 8.1. Branded Drugs
  • 8.2. Generic Drugs

9. Direct-acting Antiviral Drug Market, by Therapeutic Class

  • 9.1. Combination Therapy
  • 9.2. Ns5A Inhibitor
  • 9.3. Ns5B Inhibitor
  • 9.4. Protease Inhibitor

10. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Direct-acting Antiviral Drug Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Direct-acting Antiviral Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Direct-acting Antiviral Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Direct-acting Antiviral Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Direct-acting Antiviral Drug Market

16. China Direct-acting Antiviral Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Cipla Limited
  • 17.9. Gilead Sciences, Inc.
  • 17.10. Janssen Pharmaceuticals, Inc.
  • 17.11. Merck & Co., Inc.
  • 17.12. Mylan N.V.
  • 17.13. Roche Holding AG
  • 17.14. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)